Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial"

COVID-19 Clinical Trial

— CON-VIDA  

Official title:

Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial"

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05543408
• Other study ID #: Universidad San Jorge
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 3, 2022
• Est. completion date: October 31, 2022

Study information

• Verified date: September 2022
• Source: Universidad San Jorge
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized controlled trial of the efficacy of an individualized, progressive, exercise program (strength, cardiovascular, and breathing exercises) in recovering people from the post-COVID-19 syndrome (i.e., patients who present symptoms >12 weeks once the acute phase of the disease is over).

Description:

This is a randomized controlled trial of the efficacy of an individualized, progressive, exercise program (strength, cardiovascular, and breathing exercises) in recovering people from the post-COVID-19 syndrome (i.e., patients who present symptoms >12 weeks once the acute phase of the disease is over). The primary objective of the study is to evaluate the clinical efficacy and safety of a tailored exercise-based treatment relative to the control arm in improving the subject clinical status in both ambulatory and hospitalized post-COVID-19 syndrome patients. The main novelty of this trial compared to other exercise-based interventions is the development and proof of concept of a progressively, levelled exercise regime for people with physical activity intolerance and fatigue symptoms.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: October 31, 2022
• Est. primary completion date: August 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• People over 18 years of age.

• Persistent symptoms of COVID >3 months of duration since infection.

• Have no medical contraindications incompatible with the practice of exercise.

• Do not meet the general 2020 recommendations for physical activity established by the World Health Organization2 (i.e., at least 150-300 minutes of moderate-intensity aerobic physical activity; or at least 75-150 minutes of vigorous-intensity aerobic physical activity; or an equivalent combination of moderate- and vigorous-intensity activity throughout the week).

• Provide signed informed consent.

Exclusion Criteria:

• Presence of uncontrolled serious medical illness.

• Presence of any medical, psychological or social problem that could seriously interfere with the patient's participation in the study.

Related Conditions & MeSH terms

• COVID-19
• Long COVID
• Post-COVID-19 Syndrome
• Syndrome

Intervention

Behavioral:
• EXERCISE
individualized, progressive, exercise program

Locations

Country	Name	City	State
Spain	Lucia Sagarra-Romero	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Universidad San Jorge

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Lower Limb Strength: 30 s Sit-to-Stand test	The test starts with the participant seated on a chair (43.2 cm), arms crossed at the wrists and held against the chest. From this position, participants will conduct as much as sit-to-stand repetitions, as fast as possible, during 30 s	Baseline to 8 weeks
Primary	Change in Lower Limb Strength: 5 times Sit-to-Stand Test	Participants will have to sit and stand 5 times (as quickly as possible) from a chair (43.2 cm), arms crossed at the wrists and held against the chest. Time will be register.	Baseline to 8 weeks
Primary	Change in Handgrip Strength	Start by holding the instrument in the testing hand. Squeeze the dynamometer handle as hard as possible to obtain peak force values.	Baseline to 8 weeks
Primary	Chance in upper limbs strength: Arm Curl Biceps	The subject sits on chair, holding the weight in the hand using suitcase grip, with the arm in a vertically downward position beside the chair. Curl the arm up through a full range of motion, gradually returns to the starting position. The arm must be fully bent and then fully straightened at the elbow. The aim of this test is to do as many arm curl as possible in 30 seconds.	Baseline to 8 weeks
Primary	Change in Balance: Flamingo Balance Test	Number of seconds keeping balance with one foot on the floor and the other resting on the opposite ankle (maximum 60 s)	Baseline to 8 weeks
Primary	Change in walking speed: Brisk Walking Test	Number of seconds required to walk 30 m.	Baseline to 8 weeks
Primary	Change in cardiovascular fitness: 6-Minute Walk Test	Number of meters that can be walked in 6 min around 30 m track.	Baseline to 8 weeks
Primary	Change in pulmonary function: Inspiratory and Expiratory Pressures	The maximal inspiratory pressure (MIP) and Maximum Expiratory Pressure (MEP) reflects the respiratory muscles ability to generate force during a short quasi-static contraction.; MIP and MEP measurements are conducted with a manometer that measures mouth pressure and these depend on the motivation and co-ordination of the patient.; Procedures: MIP: from tidal breathing the patient slowly exhales as deeply as possible. During expiration the measurement is started manually. The shutter will be set as soon as the patient starts to breathe in. Now the patient is asked to inspire as fast and as powerful as possible against the shutter. The maximal inspiratory pressure will be reached after about 0.5-1 s.; MEP: from tidal breathing the patient slowly breathes in as deeply as possible. The shutter will be closed with expiration onset. Now the patient is asked to expire as fast and as powerful as possible against the shutter.	Baseline to 8 weeks
Primary	Change in pulmonary function: Peak flow Test	Peak expiratory flow measurement (peak flow) is a simple measure of the maximal flow rate that can be achieved during forceful expiration following full inspiration.; First, the patient should reset the meter by sliding the marker all the way to zero on the scale. While sitting or standing up straight, the patient should take in a full, deep breath. The mouthpiece is then placed in the patient's mouth followed by a single, fast, forceful expiration. The marker will slide outward on the numbered scale, indicating the peak expiratory flow rate for that attempt.	Baseline to 8 weeks
Secondary	Body Composition	Bio-Electrical Impedance Analysis (BIA) with 200 kg maximum capacity and 50 g error margin (TANITA BC-418MA, Tanita Corp., Tokyo, Japan).The meassurement includes: body weight (kg) body fat mass, the percentage of body fat (BF%) and the fat-free mass (FFM). Body mass index (BMI) will be calculated dividing weight (kg) by squared height (m2).	Baseline to 8 weeks
Secondary	Change in Quality of Life-SF-36	The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.	Baseline to 8 weeks
Secondary	Change in The International Physical Activity Questionnaire (IPAQ)	The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires.; Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.	Baseline to 8 weeks
Secondary	Change in Modified Medical Research Council dyspnea scale (mMRC)	The mMRC Dyspnea Scale is used to assess the degree of baseline functional disability due to dyspnea in patients with respiratory problems. The mMRC breathlessness scale ranges from grade 0 to 4 (low to high).	Baseline to 8 weeks
Secondary	Change in Modified Fatigue Impact Scale (MFIS)	The MFIS measures the impact fatigue takes on a patient's daily life. It consists of 21 items divided into 3 subdivision containing 9 physical items , 10 cognitive items and 2 psychosocial. All the items are rated from 0-4 .; The sum of all the questions are calculated where 84 is the highest score. Highest the score means higher the impact of fatigue in daily living.	Baseline to 8 weeks
Secondary	Change in Hospital Anxiety and Depression Scale (HADS)	HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression.	Baseline to 8 weeks
Secondary	Change in the short form of the DePaul Symptom Questionnaire (DSQ-SF)	The short for of the DSQ-SF is a self-report measure of demographic characteristics, myalgic encephalomyelitis and chronic fatigue syndrome symptomatology, and medical, occupational, and social history.	Baseline to 8 weeks
Secondary	Change in the Insommia Severity Index (ISI)	The ISI is composed of seven items that evaluate the severity of sleep disturbance during the past 2 week; * The first three items assess the severity of difficulties with falling sleep, maintaining sleep, and early morning awakening.; The last four items capture satisfaction with the current sleep patte, interference with daily functioning, noticeability of impairment, and degree of distress caused by the sleep problem.; The scores of each of the seven items range from 0 to 4 (0 = none; 4 = very severe), and a total score can be calculated by summing the seven items, giving a range from 0 to 28, with higher scores indicating greater insomnia severity. Total scores are interpreted as 0-7, absence of insomnia; 8-14, sub-threshold insomnia; 15-21, moderate insomnia; 22-28, severe insomnia.	Baseline to 8 weeks